Related Experiment Video
Updated: Jul 15, 2026
A Doxorubicin-Induced Murine Model of Dilated Cardiomyopathy In Vivo
Published on: May 16, 2020
Evaluation of Tideglusib as a Disease Modifying Therapy in Murine Models of Arrhythmogenic Cardiomyopathy
Nipun Malhotra1, Omer Cavus1, Michael J Wallace2
1The Frick Center for Heart Failure and Arrhythmia, Dorothy M. Davis Heart, and Lung Research Institute, The Ohio State University Wexner Medical Center, Columbus, Ohio, USA; Department of Surgery/Division of Cardiac Surgery, The Ohio State University Wexner Medical Center, Columbus, Ohio, USA.
Insights
Tideglusib shows promise in treating arrhythmogenic cardiomyopathy (ACM), an inherited heart condition. This study found Tideglusib can prevent and reverse cardiac dysfunction and reduce arrhythmias in mouse models of ACM.
Area of Science:
- Cardiology
- Genetics
- Pharmacology
Background:
- Arrhythmogenic cardiomyopathy (ACM) is an inherited cardiac disorder.
- Current treatments manage symptoms but not the underlying disease progression.
- Novel therapeutic strategies targeting ACM pathophysiology are needed.
Purpose of the Study:
- To evaluate the therapeutic potential of Tideglusib (TD) in preclinical models of ACM.
- To assess TD's efficacy in preventing and reversing cardiac dysfunction and arrhythmias in ACM mouse models.
Main Methods:
- Utilized Ank2 cardio-selective-knockout and desmoglein-2 mutant ACM mouse models.
- Administered Tideglusib (TD) to assess its effects on cardiac function and electrophysiology.
- Evaluated ventricular arrhythmia susceptibility following adrenergic stimulation.
Main Results:
- Tideglusib treatment prevented and reversed reduced cardiac function in treated ACM mice.
- TD administration led to a reduction in ventricular arrhythmias in adult mice after adrenergic stimulation.
- Demonstrated significant therapeutic benefits of TD in established ACM mouse models.
Conclusions:
- Tideglusib exhibits significant preclinical efficacy for arrhythmogenic cardiomyopathy.
- TD represents a potential disease-modifying therapy for ACM patients.
- Further investigation into TD for ACM treatment is warranted based on these findings.
Abstract:
Arrhythmogenic cardiomyopathy (ACM) is an inherited heart disease, and current pharmacological therapies are directed toward the management of electrical manifestations. To date, none address the underlying pathophysiology of this progressive condition. We evaluated the therapeutic efficacy of Tideglusib (TD) in Ank2 cardio-selective-knockout and homozygous desmoglein-2 mutant ACM mouse models. TD was able to prevent and reverse the reduced cardiac function in treated mice. Moreover, TD-treated adult mice displayed a reduction in ventricular arrhythmia following adrenergic stimulation. We provide compelling preclinical data for TD as a potential therapy for patients with ACM.
